Osiris Therapeutics (OSIR) Stock Price, News & Analysis

Company Overview

Osiris Therapeutics, Inc. is a biotechnology company specializing in regenerative medicine and cellular therapies. Headquartered in Columbia, Maryland, the company focuses on developing and commercializing treatments that harness the healing potential of human cells and tissues. Osiris’s research and development efforts have centered on mesenchymal stem cell (MSC) technology, aimed at addressing a range of orthopedic, inflammatory and graft-versus-host disease (GvHD) indications.

The company’s most widely recognized products include Prochymal®, one of the first allogeneic stem cell therapies to receive regulatory approval for the treatment of acute GvHD in pediatric patients, and Grafix®, a cryopreserved placental membrane used in advanced wound care. Beyond these flagship products, Osiris has explored additional cell-based and tissue-based offerings targeting osteoarthritis, cartilage repair and gastrointestinal conditions. The company’s pipeline has featured both proprietary and partnered programs leveraging its MSC platform.

Founded in 1992, Osiris has been a pioneer in translating cell biology research into clinical applications. Over the years, the company has built a robust intellectual property portfolio covering methods of isolating and expanding MSCs, as well as formulations for specific therapeutic uses. Osiris has conducted clinical trials across North America, Europe and Asia-Pacific, collaborating with academic medical centers and biopharmaceutical partners to advance its technologies through late-stage development.

In 2019, Osiris Therapeutics was acquired by Smith & Nephew plc, a global medical technology firm, in order to integrate its regenerative medicine capabilities into a broader orthopedics and wound care product offering. Today, the former Osiris assets continue to serve healthcare providers worldwide, supporting treatment of chronic wounds, orthopedic injuries and immune-mediated disorders through innovative cellular and tissue-based solutions.

Key Stats

• Today's Range: $18.99 to $18.99
• 50-Day Range: $18.99 to $18.99
• 52-Week Range: $7.01 to $19.30
• Volume: N/A
• Average Volume: 205,753 shs
• Market Capitalization: $655.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OSIR Stock Analysis - Frequently Asked Questions

How have OSIR shares performed this year?

Osiris Therapeutics' stock was trading at $18.99 at the beginning of the year. Since then, OSIR shares have increased by 0.0% and is now trading at $18.99.

How do I buy shares of Osiris Therapeutics?

Shares of OSIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Osiris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Osiris Therapeutics investors own include Sierra Wireless (SWIR), MiMedx Group (MDXG), Achillion Pharmaceuticals (ACHN), Mallinckrodt (MNK), Bristol Myers Squibb (BMY), Ionis Pharmaceuticals (IONS) and Mesoblast (MESO).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:OSIR
• Previous Symbol: NASDAQ:OSIR
• CIK: 1360886
• Web: www.osiristx.com
• Phone: 443-545-1800
• Fax: N/A
• Employees: 342
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,528,000
• Free Float: N/A
• Market Cap: $655.69 million
• Optionable: Not Optionable
• Beta: N/A